A Phase 2 interventional study of Fluorouracil (5-FU) and Capecitabine in Gastric Cancer, sponsored by AstraZeneca. Active, not recruiting at 71 sites in 14 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing trastuzumab deruxtecan in Stomach Neoplasms — 9 open to participants now, 11 under way, 3 of them phase 3. trastuzumab deruxtecan · Stomach Neoplasms.
Among the 14 studies testing trastuzumab deruxtecan in Stomach Neoplasms, this one is the 4th largest by enrollment, is the only one that started in 2020, is one of 6 in phase 2, reaches primary completion later than 5 of the 10 other live ones, and was the 2nd registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.
Browse Stomach Neoplasms studies →9 of the 14 studies testing trastuzumab deruxtecan in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Canada, China and 8 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 25 more countries
Ages 18+
Daiichi Sankyo · Sites in United States, Argentina, Australia and 23 more countries
Ages 18+
Jeeyun Lee · Sites in Korea, Republic of
Ages 19+
Jeeyun Lee · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab deruxtecan is the treatment under test here. Read study by study →
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 3
First in 2018; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 452 is above the median of 66 across 2,500 interventional studies indexed under Stomach Neoplasms.
Median enrollment 78 across the 14 interventional studies. Of the 3 that completed or were terminated, 2 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 14 have an industry lead sponsor. The 9 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
30 studies in Stomach Neoplasms by AstraZeneca: 10 open now, 18 under way, 3 of them phase 3. Of 12 finished, 4 (33%) have results posted.
Among the 30 studies in Stomach Neoplasms by AstraZeneca, this one is the 8th largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2020, is one of 9 in phase 2, reaches primary completion later than 7 of the 17 other live ones, and was the 12th registered.
AstraZeneca’s Stomach Neoplasms studies by the year they started, since 2007.
4 of the studies testing trastuzumab deruxtecan in Stomach Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06253650Gruppo Oncologico del Nord-OvestAdjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease | 2027-03-01 |
| NCT04379596AstraZenecaPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | 2027-05-04 |
| NCT05274048Fox Chase Cancer CenterNeratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients | 2027-06 |
| NCT07069712AstraZenecaA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | 2027-11-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies testing trastuzumab deruxtecan in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 30 in Stomach Neoplasms:
This tab as a report to print or save as PDF → With an account.
DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expressing advanced/metastatic gastric/gastroesophageal junction (GEJ) and esophageal adenocarcinoma patients.
Study hypotheses: Combination of T-DXd with cytotoxic chemotherapy and/or immunotherapy administered to subjects at the recommended phase 2 dose will show manageable safety and tolerability and preliminary anti-tumor efficacy so as to permit further clinical testing. T-DXd in combination with cytotoxic chemotherapy or immune checkpoint inhibitor administered to HER2-expressing gastric, GEJ and esophageal cancer patients who have not received prior treatment for advanced/metastatic disease will show preliminary evidence of anti-tumour activity and the potential to become a therapeutic option for this patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease Characteristics:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
T-DXd and 5-fluorouracil (5-FU)
Drug: Fluorouracil (5-FU) · Drug: Trastuzumab deruxtecan
T-DXd and capecitabine
Drug: Capecitabine · Drug: Trastuzumab deruxtecan
T-DXd and durvalumab
Biological: Durvalumab · Drug: Trastuzumab deruxtecan
T-DXd, capecitabine, and oxaliplatin
Drug: Capecitabine · Drug: Oxaliplatin · Drug: Trastuzumab deruxtecan
T-DXd, 5-FU, and durvalumab
Drug: Fluorouracil (5-FU) · Biological: Durvalumab · Drug: Trastuzumab deruxtecan
T-DXd, capecitabine, and durvalumab
Drug: Capecitabine · Biological: Durvalumab · Drug: Trastuzumab deruxtecan
Trastuzumab, 5-FU or capecitabine, and cisplatin or oxaliplatin
Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Oxaliplatin · Biological: Trastuzumab · Drug: Cisplatin
T-DXd monotherapy
Drug: Trastuzumab deruxtecan
T-DXd, 5-FU or capecitabine
Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan
T-DXd, pembrolizumab and 5-FU or capecitabine
Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Pembrolizumab
T-DXd and pembrolizumab
Drug: Trastuzumab deruxtecan · Biological: Pembrolizumab
T-DXd, pembrolizumab and 5-FU or capecitabine
Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Pembrolizumab
T-DXd, Volrustomig and 5-FU or capecitabine
Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Volrustomig
T-DXd, Volrustomig and 5-FU or capecitabine
Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Volrustomig
T-DXd, Rilvegostomig and 5-FU or capecitabine
Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Rilvegostomig
T-DXd, Rilvegostomig and 5-FU or capecitabine
Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Rilvegostomig
T-DXd, Volrustomig and 5-FU or capecitabine
Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Volrustomig
T-DXd, Volrustomig and 5-FU or capecitabine
Drug: Fluorouracil (5-FU) · Drug: Capecitabine · Drug: Trastuzumab deruxtecan · Biological: Volrustomig
5-FU: administered as an IV infusion
Capecitabine: administered orally
Durvalumab: administered as an IV infusion
Also known as: MEDI4736
Oxaliplatin: administered as an IV infusion
Trastuzumab: administered as an IV infusion
T-DXd: administered as an IV infusion
Also known as: DS-8201a, Enhertu
Cisplatin: administered as an IV infusion
Pembrolizumab: administered as an IV infusion
Volrustomig: administered as an IV infusion
Also known as: MEDI5752
Rilvegostomig: administered as an IV infusion
Also known as: AZD2936
Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0
Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0
Time frame: Safety will be assessed up to the follow-up period, approximately 24 months.
Part 1: Ocurrence of dose-limiting toxicities (DLTs)
Occurrence of dose limiting toxicities
Time frame: Safety will be assessed up to the follow-up period, approximately 24 months.
Part 1: Changes from baseline in laboratory parameters
Changes in laboratory parameters (every in appropriate units) compared to baseline results.
Time frame: Safety will be assessed up to the follow-up period, approximately 24 months.
Part 1: Changes from baseline in vital signs
Changes in vital signs results compared to baseline results.
Time frame: Safety will be assessed up to the follow-up period, approximately 24 months.
Part 1: Changes from baseline in electrocardiogram (ECG) results
Changes in ECG results compared to baseline results.
Time frame: Safety will be assessed up to the follow-up period, approximately 24 months.
Part 2, Part 3, Part 4 and Part 5: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)
Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed.
Time frame: (Endpoint: ORR) Efficacy will be assessed at an average of approximately 12 months
Part 1: Objective Response Rate (ORR)
Confirmed ORR per RECIST 1.1 is the percentage of patients with Complete Response or Partial Response that is subsequently confirmed.
Time frame: Efficacy will be assessed at an average of approximately 12 months
Part 2, Part 3, Part 4 and Part 5: Occurrence of adverse events (AEs) and serious adverse events (SAEs)
Occurrence of AEs and SAEs graded according to NCI CTCAE v5.0
Time frame: Safety will be assessed up to follow-up period, approximately 24 months
Part 2, Part 3, Part 4 and Part 5: Changes from baseline in laboratory parameters
Changes in laboratory parameters (every in appropriate units) compared to baseline results.
Time frame: Safety will be assessed up to follow-up period, approximately 24 months
Part 2, Part 3, Part 4 and Part 5: Changes from baseline in vital signs
Changes in vital signs results compared to baseline results.
Time frame: Safety will be assessed up to follow-up period, approximately 24 months
Part 2, Part 3 , Part 4 and Part 5: Changes from baseline in body weight
Changes in body weight in kilograms compared to baseline results.
Time frame: Safety will be assessed up to follow-up period, approximately 24 months
Part 2, Part 3, Part 4 and Part 5: Changes from baseline in electrocardiogram (ECG) results
Changes in ECG results compared to baseline results.
Time frame: Safety will be assessed up to follow-up period, approximately 24 months
Duration of Response (DoR)
DOR is defined as the time from the date of first documented response until the date of documented progression or death
Time frame: Until progression or death, efficacy (DoR) will be assessed up to approximately 24 months
Disease Control Rate (DCR)
DCR is the percentage of subjects who have a best overall response of complete response (CR) or partial response (PR) or stable disease (SD)
Time frame: Efficacy will be assessed at an average of approximately 12 months
Progression Free Survival (PFS)
PFS is the time from date of first dose until the date of objective disease progression or death
Time frame: Until progression or death, efficacy (PFS) will be assessed up to approximately 24 months
Overall survival (OS)
OS is the time from date of first dose until death due to any cause
Time frame: Until death, efficacy (OS) will be assessed up to approximately 24 months
Serum concentration of T-DXd, total anti-HER2 antibody, and MAAA-1181a in all arms
Individual participant data and descriptive statistics will be provided for serum concentration data at each time point for each dose level for T-DXd, total anti-HER2 antibody, MAAA-1181a
Time frame: While on study drug up to study completion, approximately 24 months
Serum concentration of durvalumab in study arms including T-DXd in combination with durvalumab
Individual participant data and descriptive statistics will be provided for serum concentration data at each time point for durvalumab.
Time frame: While on study drug up to study completion, approximately 24 months
Presence of ADAs for T-DXD, durvalumab, volrustomig and rilvegostomig (in study arms including T-DXd and durvalumab, and T-DXd and volrustomig, and T-DXd and rilvegostomig respectively)
Individual participant data and descriptive statistics will be provided for data at each time point for each dose level for T-DXd and durvalumab.
Time frame: While on study drug up to study completion, approximately 24 months
Serum concentrations of volrustomig and rilvegostomig in study arms including T-DXd in combination with volrustomig and T-DXd in combination with rilvegostomig
Individual participant data and descriptive statistics will be provided for data at each time point for rilvegostomig and volrustomig
Time frame: While on study drug up to study completion, approximately 24 months
Comparison of ORR
Comparison of objective response rate between participants using local HER2 test results and central HER2 test results from tumor samples with evaluable results
Time frame: While on study drug up to study completion, approximately 24 months
Comparison of DCR
Comparison of disease control rate between participants using local HER2 test results and central HER2 test results from tumor samples with evaluable results
Time frame: While on study drug up to study completion, approximately 24 months
Comparison of DoR
Comparison of duration of response between participants using local HER2 test results and central HER2 test results from tumor samples with evaluable results
Time frame: While on study drug up to study completion, approximately 24 months
Comparison of PFS
Comparison of progression-free survival between participants using local HER2 test results and central HER2 test results from tumor samples with evaluable results
Time frame: While on study drug up to study completion, approximately 24 months
Comparison of OS
Comparison of overall survival between participants using local HER2 test results and central HER2 test results from tumor samples with evaluable results
Time frame: While on study drug up to study completion, approximately 24 months
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Informed consent form
Time frame: Study start to completion date
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Started Jun 2020 (actual). Primary completion is estimated for May 2027, 83 months after the start.
Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's planned 83 months is above that.
Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Trastuzumab deruxtecan · Volrustomig · Rilvegostomig